RT Journal Article
SR Electronic
T1 Concomitant medications and efficacy of nintedanib in patients with IPF
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA4891
DO 10.1183/1393003.congress-2017.PA4891
VO 50
IS suppl 61
A1 Kreuter, Michael
A1 Song, Jin Woo
A1 Huggins, John T.
A1 Wallaert, Benoit
A1 Stansen, Wibke
A1 Quaresma, Manuel
A1 Crestani, Bruno
YR 2017
UL http://erj.ersjournals.com/content/50/suppl_61/PA4891.abstract
AB Introduction: In the two INPULSIS trials in patients with IPF, the annual rate of decline in FVC was reduced in patients treated with nintedanib 150 mg twice daily versus placebo. Patients who completed an INPULSIS trial could receive open-label nintedanib in the extension trial INPULSIS-ON. The influence of medications commonly prescribed to treat comorbid conditions on the effect of nintedanib is unknown.Aim: To assess whether concomitant medication use at the start of INPULSIS and INPULSIS-ON influenced the effect of nintedanib on FVC decline.Methods: The annual rate of decline in FVC over 52 weeks in INPULSIS and over 48 weeks in INPULSIS-ON in subgroups defined by concomitant medication use at baseline was assessed descriptively.Results: The annual rates of decline in FVC over 52 weeks in INPULSIS and over 48 weeks in INPULSIS-ON were consistent across subgroups by concomitant medication use at baseline, including anti-acid therapy and corticosteroids (Table). There was a numerical difference in the annual rate of decline in FVC between subgroups defined by use of N-acetylcysteine or bronchodilators in INPULSIS-ON; however, as the number of patients in some subgroups was small, these results should be interpreted with caution.Conclusion: Data from INPULSIS and INPULSIS-ON demonstrated a consistent effect of nintedanib on the annual rate of decline in FVC in patients with IPF irrespective of concomitant medication use at baseline.